Results 161 to 170 of about 40,867 (262)

Comparison of KN012, a denosumab biosimilar, versus reference denosumab in Chinese postmenopausal women with osteoporosis: efficacy, safety, and population pharmacokinetics in a 12-month phase III study. [PDF]

Bone Rep
Zhu X, Liu J, Mao Y, Li J, Shao F, Lin H.   +5 more
europepmc   +1 more source

Denosumab and bone loss in uncemented total hip arthroplasty: a secondary 5-year follow-up of a randomized controlled trial. [PDF]

Acta Orthop
Sköld C, Hailer NP, Mallmin H.
europepmc   +1 more source

Changes in serum vitamin D and PTH values using denosumab with or without bisphosphonate pre-treatment in osteoporotic patients: a short-term study [PDF]

, 2015

core   +1 more source

Bone turnover in postmenopausal women during denosumab treatment: Biomarker analysis in naive and discontinuing patients. [PDF]

Bone Rep
Bartosik M, Wolf E, Simon A, von Brackel FN, Windels O, Klostermeier UC, Barvencik F, Amling M, Oheim R.   +8 more
europepmc   +1 more source

Efficacy and safety of denosumab biosimilars in the treatment of postmenopausal osteoporosis: A systematic review of randomized clinical trials. [PDF]

Clin Exp Med
Shakibaei F, Malekshahi S, Heidari N, Heidari A.   +3 more
europepmc   +1 more source

In silico exploration of osteoclast precursor inhibition for preventing rapid bone loss after denosumab discontinuation. [PDF]

NPJ Syst Biol Appl
Kim YK, Kameo Y, Tanaka S, Adachi T.
europepmc   +1 more source

Functional Outcome of Curettage and Chemical Cauterization with Bone Grafting and Fixation with Neo-Adjuvant Denosumab Therapy in a Case of Giant Cell Tumor of Navicular Bone of a Young Adult - A Case Report. [PDF]

J Orthop Case Rep
Honwadkar NK, Pawar ED, Gavhale SV, Lalchandani V, V AT, Yadav A.   +5 more
europepmc   +1 more source

Atypical femoral fracture and jaw osteonecrosis under high doses of denosumab, healed with the aid of low dose of denosumab: a case report. [PDF]

Front Endocrinol (Lausanne)
Lassoued H, Lamy O, Francioli C, Gonzalez Rodriguez E.   +3 more
europepmc   +1 more source

Protocol summary and statistical analysis plan for the bone loss prevention with zoledronic acid or denosumab in critically ill adults (BONE ZONE) trial. [PDF]

Crit Care Resusc
Orford N, Serpa Neto A, Nair P, Bone A, Center JR, Hodgson C, Kotowicz MA, Litton E, Reynolds C, Trapani T, Young P, Venkatesh B, Bone Zone Investigators, ANZICS Clinical Trials Group.   +13 more
europepmc   +1 more source

Denosumab in pediatric patients with fibrous dysplasia/McCune-Albright syndrome: a single-center, open-labeled study. [PDF]

Front Endocrinol (Lausanne)
Ouyang Q, Jiajue R, Zhou R, Qi W, Li X, Cui L, Chi Y, Pang Q, Gong Y, Liu W, Jiang Y, Wang O, Li M, Xing X, Xia W.   +14 more
europepmc   +1 more source